Abstract
NSCLC remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. Front-line treatment of NSCLC has been improved by programmed cell death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors. KEYNOTE-189 showed that the addition of pembrolizumab to pemetrexed and platinum-based CT significantly improved overall survival (OS) and progression-free survival (PFS) in patients with untreated non-squamous metastatic NSCLC regardless of PD-L1 expression (Gandhi New Engl J Med 2018).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
